QIMR Berghofer Engages with Qubigen to Advance AI-Driven Research in Cancer Pathways

Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer, one of Australia’s leading medical research institutes. The agreement establishes a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression. By combining Qubigen’s computational modelling and quantum chemistry capabilities with QIMR Berghofer’s deep expertise in translational cancer biology, this partnership aims to illuminate new therapeutic opportunities in a field with a high unmet medical need.

Using Molecular Modelling to Target Cancer Vulnerabilities

Recent discoveries at QIMR Berghofer have revealed a novel mechanism that sustains inflammation and tumour growth in cancers, offering a promising new opportunity for therapeutic intervention. Under the agreement, Qubigen will deploy its advanced computational modelling infrastructure to identify a series of chemical compounds predicted to disrupt interactions between key proteins involved in the cancer pathway.

Bridging Computational Discovery and Experimental Validation

Qubigen’s proprietary technology combines molecular modelling with GPU-accelerated, quantum chemistry-based virtual screening to identify small molecules targeting highly novel protein targets. This technology will be used to model complex formation between key proteins, map potential therapeutic binding sites, and screen for compounds predicted to block the interaction. The most promising candidates will be provided to QIMR Berghofer for in vitro evaluation to confirm their ability to inhibit protein-protein binding in tumour cells. By uniting advanced computational methods with leading cancer biology, the project aims to accelerate the discovery of new treatment strategies for cancers.

Qubigen: accelerate drug design without exposing secrets

Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.

enquiries@qubigen.com

QIMR Berghofer

QIMR Berghofer is a world-leading medical research institute based in Brisbane, Australia, dedicated to improving health through impactful research. With a proud legacy dating back to 1945, the Institute is home to more than 1,000 scientists, clinicians, students and staff, working across four key programs of Cancer Research, Infection and Inflammation, Population Health, and Brain and Mental Health. QIMR Berghofer has a strong track record in commercialisation, working with industry, government, and investors to translate fundamental research discoveries into real-world impact.

For more information, visit www.qimrb.edu.au